Associated Papers
Intrinsic Factors Influencing Simvastatin and Simvastatin Acid Pharmacokinetics: Age-Related Studies in Thai Adults and Cross-Population Comparisons.
Srimatimanon T et al.
Clinical and Translational Science, 2026
Pharmacogenetic hSLCO1B1*14-Guided Dosing of Methotrexate in Transgenic Arthritic Mice Normalizes Exposure and Response.
Gooden F et al.
Clinical and Translational Science, 2026
Molecular analysis of the evolutionary history of endometrial and ovarian carcinoma in Lynch syndrome.
Kauppinen AK et al.
International Journal of Cancer, 2025
Retrospective Evaluation of the Impact of SLCO1B1 Variation on Statin Effectiveness.
Ahmed Feldman M et al.
Journal of Personalized Medicine, 2025
Transporter Genes and statin-induced Hepatotoxicity.
Choi SA et al.
Cardiovascular Drugs and Therapy, 2025
Unveiling hidden risks: pharmacogenetic insights from a cross-sectional study of statin therapy in the Indian population.
Naushad SM et al.
Pharmacological Reports : Pr, 2025
Identification of Genetic Variants Associated with Pravastatin and Pitavastatin Pharmacokinetics.
Mykkänen AJH et al.
Clinical Pharmacology and Therapeutics, 2025
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between SLCO1B1 and statins and CYP2C9 and sulfonylureas.
Wolthuis DFGJ et al.
European Journal of Human Genetics : Ejhg, 2025
Value of Pharmacogenetic Testing Assessed with Real-World Drug Utilization and Genotype Data.
Litonius K et al.
Clinical Pharmacology and Therapeutics, 2025
Pharmacogenetics in Tuberculosis-HIV Coinfected Populations: A Systematic Review of Genetic Variants Influencing Antiretroviral and Anti-Tuberculosis Drug Response.
Hardi H et al.
Journal of Multidisciplinary Healthcare, 2025
Genome-Wide Association Study of Atorvastatin Pharmacokinetics: Associations With SLCO1B1, UGT1A3, and LPP.
Mykkänen AJH et al.
Clinical Pharmacology and Therapeutics, 2024
SLCO1B1 Exome Sequencing and Statin Treatment Response in 64,000 UK Biobank Patients.
Türkmen D et al.
International Journal of Molecular Sciences, 2024
Non-targeted metabolomics for the identification of plasma metabolites associated with organic anion transporting polypeptide 1B1 function.
Hämäläinen K et al.
Clinical and Translational Science, 2024
Effect of donor GSTM3 rs7483 genetic variant on tacrolimus elimination in the early period after liver transplantation.
Zhang T et al.
Peerj, 2024
Do Gene Polymorphisms Play a Role in Newborn Hyperbilirubinemia?
Hakan N et al.
Balkan Journal of Medical Genetics : Bjmg, 2023
A gene risk score using missense variants in SLCO1B1 is associated with earlier onset statin intolerance.
Bigossi M et al.
European Heart Journal. Cardiovascular Pharmacotherapy, 2023
Characterization of Bile Acid Sulfate Conjugates as Substrates of Human Organic Anion Transporting Polypeptides.
Orozco CC et al.
Molecular Pharmaceutics, 2023
Associations between four polymorphisms of the SLCO1B1 and effectiveness of the statins: a meta-analysis.
Nguyen HH et al.
Pharmacogenetics and Genomics, 2023
Pharmacogenomics of response to statin treatment and susceptibility to statin-induced adverse drug reactions in Asians: a scoping review.
Yow HY et al.
Asian Biomedicine : Research, Reviews and News, 2023
Association of Inherited Genetic Factors With Drug-Induced Hepatic Damage Among Children With Acute Lymphoblastic Leukemia.
Yang W et al.
Jama Network Open, 2022
Polymorphisms of SLCO1B1 Gene in Sundanese Ethnic Population of Tuberculosis Patients in Indonesia.
Santoso P et al.
Acta Medica Indonesiana, 2022
Genomewide Association Study of Simvastatin Pharmacokinetics.
Mykkänen AJH et al.
Clinical Pharmacology and Therapeutics, 2022
SLCO1B1 and SLC10A1 polymorphism and plasma rifampin concentrations in patients with co-morbidity tuberculosis-diabetes mellitus in Baja California, Mexico.
Perea-Jacobo R et al.
Tuberculosis (edinburgh, Scotland), 2022
Genetic Variants and Drug Efficacy in Tuberculosis: A Step toward Personalized Therapy.
Khan A et al.
Global Medical Genetics, 2022
Clinical pharmacogenetic analysis in 5,001 individuals with diagnostic Exome Sequencing data.
Lanillos J et al.
Npj Genomic Medicine, 2022
Pharmacogenomics of statins: lipid response and other outcomes in Brazilian cohorts.
Dagli-Hernandez C et al.
Pharmacological Reports : Pr, 2022
Is Pharmacogenetic Panel Testing Applicable to Low-Dose Methotrexate in Rheumatoid Arthritis? - A Case Report.
Jeiziner C et al.
Pharmacogenomics and Personalized Medicine, 2022
Effect of Genetic Variations in Drug-Metabolizing Enzymes and Drug Transporters on the Pharmacokinetics of Rifamycins: A Systematic Review.
Sileshi T et al.
Pharmacogenomics and Personalized Medicine, 2022
Characterization of ADME Gene Variation in Colombian Population by Exome Sequencing.
Silgado-Guzmán DF et al.
Frontiers in Pharmacology, 2022
Performance of Plasma Coproporphyrin I and III as OATP1B1 Biomarkers in Humans.
Neuvonen M et al.
Clinical Pharmacology and Therapeutics, 2021
Toward pharmacogenetic SLCO1B1-guided dosing of methotrexate in arthritis using a murine Slco1b2 knockout model.
Taylor ZL et al.
Clinical and Translational Science, 2021
Effect of efavirenz-based ART on the pharmacokinetics of rifampicin and its primary metabolite in patients coinfected with TB and HIV.
Sundell J et al.
The Journal of Antimicrobial Chemotherapy, 2021
Relationship among genetic polymorphism of SLCO1B1, rifampicin exposure and clinical outcomes in patients with active pulmonary tuberculosis.
Kim ES et al.
British Journal of Clinical Pharmacology, 2021
SLCO1B1: Application and Limitations of Deep Mutational Scanning for Genomic Missense Variant Function.
Zhang L et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2021
Identification of Glycochenodeoxycholate 3-O-Glucuronide and Glycodeoxycholate 3-O-Glucuronide as Highly Sensitive and Specific OATP1B1 Biomarkers.
Neuvonen M et al.
Clinical Pharmacology and Therapeutics, 2021
Decoding variants in drug-metabolizing enzymes and transporters in solid tumor patients by whole-exome sequencing.
Aboul-Soud MAM et al.
Saudi Journal of Biological Sciences, 2021
Rifampicin Transport by OATP1B1 Variants.
Litjens CHC et al.
Antimicrobial Agents and Chemotherapy, 2020
Genetic Diversity in Drug Transporters: Impact in African Populations.
Rajman I et al.
Clinical and Translational Science, 2020
Elucidation of OATP1B1 and 1B3 transporter function using transgenic rodent models and commonly known single nucleotide polymorphisms.
Choudhuri S et al.
Toxicology and Applied Pharmacology, 2020
Influence of Single Nucleotide Polymorphisms on Rifampin Pharmacokinetics in Tuberculosis Patients.
Thomas L et al.
Antibiotics (basel, Switzerland), 2020
Impact of SLCO1B1 Genetic Variation on Rosuvastatin Systemic Exposure in Pediatric Hypercholesterolemia.
Wagner JB et al.
Clinical and Translational Science, 2020
Genetic polymorphisms of human hepatic OATPs: functional consequences and effect on drug pharmacokinetics.
Nie Y et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2020
The influence of genetic polymorphisms in drug metabolism enzymes and transporters on the pharmacokinetics of different fluvastatin formulations.
Xiang Q et al.
Asian Journal of Pharmaceutical Sciences, 2020
Enantiospecific Pharmacogenomics of Fluvastatin.
Hirvensalo P et al.
Clinical Pharmacology and Therapeutics, 2019
SLCO1B1 c.388A > G variant incidence and the severity of hyperbilirubinemia in Indonesian neonates.
Amandito R et al.
Bmc Pediatrics, 2019
Targeted next generation sequencing as a tool for precision medicine.
Gulilat M et al.
Bmc Medical Genomics, 2019